Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Rating

Rating methodology
Latest close (chg%)203.75+1.30%
Buy price
203.75
Target price280.00
Sell price179.99
P/E TTM-103.56
P/E-168.14
Confidence70%
Risk score60/100
AI Summary
The decision synthesizes strong fundamental growth (36% revenue growth, expanding gross margins to ~65%), near-term catalysts (Zenith launch, patent victory), and a technical consolidation phase rather than a downtrend. A defined risk management plan with a stop-loss below key support addresses volatility concerns while positioning for upside.

Alpha Score

0-10
  • Trend（Score 4/10）

    NTRA is in a consolidation phase within a broader downtrend, showing high volatility and no clear directional bias, with a neutral to cautious outlook.

  • Valuation（Score 5/10）

    Valuation must be based on sales multiples due to lack of earnings. The stock trades at a high PS ratio of 12.61, reflecting market pricing of exceptional growth. Current price appears moderately undervalued relative to recent trading history and reasonable sales-based valuation range, but remains richly valued on an absolute basis.

  • Financial strength（Score 6/10）
    Financial health shows strength in liquidity and manageable debt structure, but core issue is persistent cash burn due to substantial net losses. Company is in high-investment, growth-focused phase that consumes cash.
  • Profitability（Score 3/10）
    Profitability profile shows strong top-line growth with accelerating revenue but persistent bottom-line losses. Gross margins are healthy and improving, but high operating expenses lead to negative net margins and negative return metrics.
  • Sentiment（Score 8/10）
    Natera's recent news flow is overwhelmingly positive, with strong product execution, legal victories, financial improvement, and high-profile institutional support suggesting a potential valuation gap after recent pullback.
Latest price
$203.75+1.30%
Market cap29.09B
P/E TTM-103.56
P/E-168.14
Volume1M
Turnover203.15M